非小细胞肺癌外周血CD4^＋CD25^＋FoxP3^＋调节T细胞分析

目的分析非小细胞肺癌（NSCLC）患者外周血CD4^＋CD25^＋FoxP3^＋调节T细胞（Treg）占CD4^＋T细胞的比例变化,探讨其临床意义。方法采用流式细胞仪检测32例非小细胞肺癌患者和15例正常健康者（对照组）外周血中CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞的比例。结果健康对照纽外周血CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞比例为（0．54±0．51）％;NSCLC患者外周血CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞比例为（1．40±0．98）％。两组比较差异有统计学意义（P〈0．01）。结论NSCLC患者外周血CD4^＋CD25^＋FoxP3^＋Treg占CD4^＋T细胞的比例明显升高,提示与肺癌免l癌逃逸有美。     

体外培养扩增CD4+CD25+调节性T细胞的实验观察

目的 观察细胞因子体外培养扩增CD4+CD25+调节性T细胞(Treg)的作用,以便从体外获取大量Treg细胞.方法 将从C57BL/6幼稚小鼠脾脏和淋巴结中提取的Treg与从DBA/2小鼠骨髓中提取的成熟树突细胞(mDC)混合培养,并分别加入白细胞介素-2(IL-2)、IL-4或IL-15,检测Treg增殖和凋亡的情况,与不加入任何细胞因子为对照.分别将培养获得的Treg与C57BL/6幼稚小鼠的效应性T细胞(Teff)混合培养,测定扩增后的Treg对Teff的抑制活性.检测扩增后Treg的Foxp3表达,从而证明培养获得的Treg仍保持其表型.结果 在保持其对Teff抑制活性的同时,IL-2组、IL-4组、IL-15组Treg的增殖细胞前体频率分别为31.3%、28.9%、34.5%,明显高于对照组(14.5%),均P＜0.05;增殖指数分别为1.9、1.7、1.8,明显高于对照组(1.5),均P＜0.05.IL-2组、IL-4组、IL-15组Treg的凋亡细胞比例分别为12.8%、11.4%、12.7%,均明显低于对照组(28.9%),均P＜0.05.扩增后的Treg仍高表达Foxp3(91.75%).结论 IL-4、IL-15和IL-2一样,具有促进Treg增殖、减少其凋亡的作用,并同时保持对Teff的抑制功能.扩增后的Treg仍保持其表型,高表达Foxp3.     

FOLFOX方案化疗对胃癌术后患者外周血CD4+CD25+调节性T细胞细胞增殖及功能的影响

目的探讨FOLFOX方案化疗对胃癌术后患者外周血CD4+CD25+调节性T细胞(Treg细胞)比例及功能的影响。方法选择43例胃癌术后化疗患者,于化疗前1天、化疗结束后第5天采集外周血。采用流式细胞法检测外周血Treg细胞的比例;RT-PCR法检测外周血Treg细胞FoxP-3 mRNA表达水平;将分选的Treg细胞和CD4+CD25-T细胞按单纯Treg细胞组、1∶1混合细胞组,单纯CD4+CD25-T细胞组培养,3H-TdR掺入法检测Treg细胞体外抑制CD4+CD25-T细胞增殖的能力。结果 43例胃癌患者化疗前1天外周血Treg细胞占CD4+T细胞的比例为17.63%±6.31%,化疗后降至13.79%±4.82%(P<0.01);化疗后FoxP-3表达水平较化疗前显著下降(P<0.01);化疗后Treg细胞对CD4+CD25-T细胞的增殖抑制率由化疗前的54.64%±5.15%下降至24.63%±2.34%(P<0.01)。结论 FOLFOX化疗方案可减少胃癌患者外周血Treg细胞数量,下调其表面标志物FoxP3基因的表达水平,减弱Treg细胞的免疫抑制功能,有利于诱生抗肿瘤免疫效应。     

系统性红斑狼疮患者外周血CD4+CD25high Treg上PD-1分子的表达分析

目的：检测系统性红斑狼疮（systemic lupus erythematosus,SLE）患者外周血CD4＋CD25highTreg及其程序性死亡受体-1（programmed death-1,PD-1）分子的表达,探讨Treg和PD-1表达在SLE中的意义。方法：流式细胞仪检测SLE患者组、正常对照组外周血CD4＋T细胞中的CD4＋CD25highTreg和CD4＋CD25lowT细胞的比例,及其PD-1分子的表达率。结果：CD4＋CD25highTreg在SLE患者组外周血中CD4＋T细胞的比例（0.63±0.31）%与正常对照组（2.07±0.74）%相比明显降低（P〈0.05）,该亚群细胞上PD-1＋的百分率（24.99±18.65）%与对照组（6.97±1.92）%相比显著增高（P〈0.05）;CD4＋CD25lowT细胞的百分率（13.40±8.47）%及其PD-1＋的百分率（2.70±3.06）%与正常对照组（20.16±11.89）%和（0.43±0.36）%相比,差异有统计学意义（P〈0.05）。结论：外周血CD4＋CD25highTreg数量下降及其PD-1分子表达上调可能在SLE中有重要意义。     

NOD小鼠CD4^＋CD25^＋调节性T细胞功能变化研究

目的：观察NOD小鼠CD4^＋CD25^＋调节性T细胞的功能变化。方法：流式细胞仪分析NOD小鼠胰腺引流淋巴结（PLN）CD4^＋CD25^＋T细胞频率,CD4^＋CD25^＋T细胞中FoxP3^＋细胞的比例,CD4^＋CD25^＋FoxP3^＋T细胞的FoxP3平均荧光强度（MFI）;检测CD4^＋CD25^＋调节性T细胞的抑制功能。结果：在不同的年龄阶段,CD4^＋CD25^＋调节性T细胞数量未发生明显变化,而随时间的推移,CD4^＋CD25^＋调节性T细胞中FoxP3表达水平降低,CD4^＋CD25^＋调节性T细胞的功能也下降。结论：CD4^＋CD25^＋调节性T细胞的抑制功能降低可能是NOD小鼠糖尿病发作的根本原因。     

ART治疗对HIV感染者CD4+FoxP3+T细胞水平的影响

目的:探索抗逆转录病毒疗法(ART)治疗在HIV-1疾病进程中对调节性T细胞(Treg细胞)的影响,并探讨Treg细胞频率在HIV-1疾病进程中的作用.方法:抽取114例(男96例、女18例)HIV-1阳性患者及17例健康对照者外周血,应用流式细胞术检测Treg细胞,并分析其表达水平(频率和绝对数)在 HIV-1疾病进程中的变化趋势及其与CD4+细胞绝对数之间的相关性.结果:随着HIV-1感染者病情进展,患者外周血中Treg细胞绝对数趋向下降并且与CD4+T细胞绝对数呈正相关,而Treg细胞频率趋向升高并且与CD4+T细胞绝对数呈负相关.Treg细胞频率及绝对数在ART治疗无症状HIV-1阳性感染者中显著降低,而在AIDS患者中却显著升高.结论:Treg细胞参与艾滋病免疫发病过程,并且在HIV-1感染的不同阶段,ART治疗对Treg细胞水平具有一定的影响,提示通过控制Treg细胞的水平可能有助于HIV-1感染疾病的临床控制.     

人天然CD4+CD25+调节性T细胞的体外扩增培养及鉴定

目的：建立有效的体外培养扩增人天然CD4+CD25+调节性T细胞(regulatory T cell,Treg)的体系,并检测扩 增细胞的表型及体外免疫抑制功能,为Treg应用于临床免疫治疗提供实验基础。方法：免疫磁珠分离(MACS)方法从 人外周血单个核细胞中分离CD4+CD25+Treg,加入抗CD3/CD28包被磁珠刺激扩增;用台盼蓝染色法测定新鲜分选 的和扩增的Treg的数量和活性,用流式细胞法检测新鲜的和扩增的Treg主要表型标志和纯度,用混合淋巴细胞反应 (mixed lymphocyte reaction,MLR)法检测扩增的Treg对羧基荧光素二醋酸盐琥珀酰亚胺酶(CFSE)标记的自体和异体的 CD4+CD25–T细胞增殖的抑制作用。结果：扩增3周后Treg数目约为新鲜分选细胞数的2 000倍(由5.23×105±1.52×105扩增 至1.02×109±0.20×109),活性>97%。扩增3周后的Treg与新鲜分选细胞保持了相似的表型特征：CD4⁺CD25⁺FoxP3⁺三阳细 胞约占(94.22±2.12)%,与新鲜分选细胞相似。扩增3周后的Treg对自体和异体的CD4+CD25–T细胞的增殖均有明显的抑 制作用,抑制率随着效靶比浓度的增高而增高(P<0.01),而且其各浓度梯度对自体和异体CD4⁺CD25^–T细胞的抑制率 无明显差异(P>0.05)。结论：创建的分离和体外扩增人CD4⁺CD25⁺Treg的方法,可以大量扩增出高纯度且保留其免疫 抑制功能的Treg,解决了Treg数目少的问题,有利于进一步的免疫研究和治疗。     

CD4+CD25+、CD4+CD25hig调节性T细胞和Foxp3 mRNA在婴幼儿喘息中的表达及意义

目的探讨婴幼儿喘息CD4+CD25+、CD4+CD25hig调节性T细胞(Treg)和叉头/翼状螺旋转录因子(Foxp3)mRNA的表达及意义。方法采用流式细胞术检测51例首次喘息婴幼儿外周血CD4+CD25+Treg和CD4+CD25hig Treg的比例,RT-PCR检测Foxp3mRNA的表达量,酶联免疫吸附法(ELASA)检测总IgE水平,并与正常婴幼儿对照。结果喘息婴幼儿外周血CD4+CD25+Treg、CD4+CD25higTreg占CD4+T细胞的百分比分别为(6.31+2.96)%和(3.52+1.46)%,均明显低于健康对照组(P<0.01);特应征喘息组CD4+CD25+Treg、CD4+CD25higTreg及Foxp3mRNA表达均低于非特应征喘息组(P<0.05)。喘息患儿CD4+CD25higTreg百分率及Foxp3mRNA表达与血清总IgE之间呈显著负相关(r=-0.75,r=-0.61,P<0.01),而CD4+CD25+Treg百分比与血清总IgE存在正相关(r=0.36,P<0.05)。结论 CD4+CD25+Treg、CD4+CD25hig Treg及Foxp3mRNA在婴幼儿喘息的发病中起重要作用。     

慢性乙型肝炎患者CD4+ CD25+调节性T细胞免疫抑制功能的研究

目的 探讨慢性乙型肝炎患者CD4+ CD25+调节性T细胞(Treg)免疫抑制功能.方法 收集北京大学人民医院22例慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMC)以及18名健康对照的PBMC标本,以流式分析对PBMC中CD4+ CD25+ Treg的频率进行分析;5-溴脱氧尿嘧啶核苷(BrdU)掺入法评价CD4+ CD25+ Treg的免疫抑制功能;并同时通过磁珠分选去除CHB患者PBMC中的CD4+ CD25+ Treg,分别以MHC-肽-五聚体法和酶联斑点免疫法(Elispot)检测HBVcore18-27抗原肽刺激对HBV特异性的细胞毒性T淋巴细胞(CTLs)的频率以及IFN-γ的分泌.结果 CHB患者外周血中CD4+ CD25+ Treg细胞群所占CD4+T细胞群的比例明显高于健康对照(t=3.74,P＜0.01);CHB患者CD4+ CD25+ Treg细胞可非特异抑制自身活化的CD4+ CD25- T细胞,并呈剂量依赖的特点,且抑制能力与健康对照相比无明显差异;在经HBVcore18-27抗原肽诱导条件下,去除CD4+ CD25+ Treg CHB患者,HBVcore18-27特异性CTLs的频率以及CTLs分泌IFN-γ的频数与未去除CD4+ CD25+ Treg组比出现显著上调(t=4.75,t=7.828,P＜0.01).结论 CHB患者循环中CD4+ CD25+ Treg细胞频率升高.在体外去除CHB患者PBMC的CD4+ CD25+ Treg后可显著地增强HBV抗原诱导的抗HBV细胞免疫应答.     

干扰素治疗慢性乙型肝炎患者B7-H1/PD-1表达与早期病毒学应答的关系

目的初步探讨聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者T淋巴细胞和mDCs上共刺激分子B7-H1/PD-1表达与早期病毒学应答的关系。方法纵向观察接受聚乙二醇干扰素α-2a治疗的28例CHB患者其mDCs和T细胞上B7-H1/PD-1的表达变化,分析B7-H1/PD-1表达与聚乙二醇干扰素α-2a治疗效果之间的关系。结果聚乙二醇干扰素α-2a治疗12周时,早期病毒学应答组患者B7-H1在CD3＋T细胞、CD4＋T细胞、CD8＋T细胞、mDC上表达及PD-1在CD3＋T细胞、CD4＋T细胞、CD8＋T细胞上表达水平均明显低于非早期病毒学应答组患者,两组差异显著,P值分别为0.009,0.009,0.009,0.042,0.004,0.017,0.004。结论聚乙二醇干扰素α-2a抗病毒疗效可能与CHB患者mDCs和T细胞上B7-H1/PD-1的表达相关。     

Association of T regulatory cells with natural course and response to treatment with interferon-α in patients with chronic hepatitis B infection

Background  Regulatory T cell populations, particularly CD4⁺CD25⁺ T regulatory cells, have been implicated in the persistence of hepatitis B virus (HBV) infection. However, no clear relationship has been established between the frequency of CD4⁺CD25⁺ T regulatory cells in the peripheral blood and either the disease phases in the natural history of chronic HBV infection or in the response to interferon-α therapy.

Methods  In the present study, three different common markers of CD4⁺CD25⁺ T regulatory cells were used to determine the numbers of T regulatory cells in healthy controls and in patients with chronic HBV infection.

Results  No significant difference was found when samples were gated for CD25^hi and CD25⁺FoxP3⁺ T cells. A significant correlation was found between the number of CD4⁺ Treg cells that gated with CD25⁺FoxP3⁺ and CD25⁺CD127^low/- in healthy controls and in patients with chronic hepatitis B (CHB) (r=0.67, 0.59; P <0.01). The percentages of Treg cells were (8.56±2.01)% in asymptomatic carriers (Asc), (8.74±3.04)% in inactive HBsAg carriers, (10.7±2.93)% in CHB and (7.42±1.28)% in healthy controls (F=11.1, P <0.001). The percentage of Treg cells in patients with CHB was higher than in asymptomatic HBV patients, inactive HBsAg carriers, or healthy controls (P <0.01). The proportion of CD4⁺CD25⁺CD127^low/- T cells in patients who responded to interferon-α was (11.9±3.3)%, (9.1±2.4)% and (9.0±2.9)% at baseline, week 12 and week 24 after treatment, respectively (Z=2.42, P <0.05; Z=2.67, P <0.01).

Conclusions  These results suggest that the proportion of the CD4⁺CD25⁺ regulatory T cells might be affected by the application of different markers in process to detect T regulatory cells. The frequency of Treg cells was increased in patients with CHB, which might be associated with the disease activity of these patients and contribute to prevention of extensive liver damage. A decline in Treg cells at week 12 of treatment might be associated with a better response to treatment with interferon-α.

     

CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25− naive T cells display more potent regulatory ability in vitro

Background Rapamycin （RAPA） is a relatively new immunosuppressant drug that functions as a serine/threonine kinase inhibitor to prevent rejection in organ transplantation. RAPA blocks activation of T-effector （Teff） cells by inhibiting the response to interleukin-2. Recently, RAPA was also shown to selectively expand the T-regulator （Treg） cell population. To date, no studies have examined the mechanism by which RAPA converts Teff cells to Treg cells. Methods Peripheral CD4＋CD25- naive T cells were cultivated with RAPA and B cells as antigen-presenting cells （APCs） in vitro. CD4＋CD25- T cells were harvested after 6 days and analyzed for expression of forkhead box protein 3 （Foxp3） using flow cytometry. CD4＋CD25＋CD127- subsets as the converted Tregs were isolated from the mixed lymphocyte reactions （MLR） with CD127 negative selection, followed by CD4 and CD25 positive selection using microbeads and magnetic separation column （MSC）. Moreover, mRNA was extracted from converted Tregs and C57BL/6 naive CD4＋CD25＋ T cells and Foxp3 levels were examined by quantitative real-time polymerase chain reaction （rt-PCR）. A total of 1×105 carboxyfluorescein succinimidyl ester （CFSE）-labeled naive CD4＋CD25- T cells/well from C57BL/6 mice were cocultured with DBA/2 or C3H maturation of dendritic cells （mDCs） （0.25×105/well） in 96-well round-bottom plates for 6 days. Then 1×105 or 0.25×105 converted Treg cells were added to every well as regulatory cells. Cells were harvested after 6 days of culture and analyzed for proliferation of CFSE-labeled naive CD4＋CD25- T cells using flow cytometry. Data were analyzed using CellQuest software.Results We found that RAPA can convert peripheral CD4＋CD25- naive T Cells to CD4＋Foxp3＋ Treg cells using B cells as APCs, and this subtype of Treg can potently suppress Teff proliferation and maintain antigenic specificity. Conclusion Our findings provide evidence that RAPA induces Treg cell conversion from Teff cells and uncovers an additional mechanism for tolerance induction by RAPA.     

CD4~+CD25~+FOXP3~+Treg细胞在高危多发性骨髓瘤治疗中预测复发及治疗意义

目的 探讨CD4+CD25+FOXP3+调节性T淋巴细胞(Treg)在高危多发性骨髓瘤治疗中预测复发及治疗意义。方法 选择2018年3月至2019年3月我院收治的126例高危多发性骨髓瘤患者为病例组,同期在我院体检健康者100例为对照组,比较病例组和对照组不同化疗疗效、不同复发情况患者外周血CD4+CD25+FOXP3+Treg细胞比例,用Spearman相关性分析CD4+CD25+FOXP3+Treg细胞比例与患者复发的相关性,用受试者工作特征曲线(ROC)分析CD4+CD25+FOXP3+Treg细胞比例预测患者复发的价值,并进行CD4+CD25+FOXP3+Treg细胞比例不同患者随访期间无进展生存的Kaplan-Meier分析。结果 病例组CD4+CD25+FOXP3+Treg细胞比例远高于对照组(P0.001);化疗无效患者CD4+CD25+FOXP3+Treg细胞比例远高于化疗有效患者(P0.001);复发患者CD4+CD25+FOXP3+Treg细胞比例远高于未复发患者(P0.001);CD4+CD25+FOXP3+Treg细胞比例与患者复发呈正相关(P0.05);CD4+CD25+FOXP3+Treg细胞比例预测患者复发的AUC(95%CI:0.759～0.856)为0.809,敏感性为62.80%,特异性为95.80%,准确性为89.30%,截断值为3.66%。CD4+CD25+FOXP3+Treg细胞比例3.66%组随访期间无进展生存率显著低于CD4+CD25+FOXP3+Treg细胞比例3.66%组(P0.05)。结论 CD4+CD25+FOXP3+Treg细胞比例在高危多发性骨髓瘤患者外周血中呈上升状态,其水平检测对于化疗后复发有一定预测价值,有助于临床预测化疗效果、监测早期复发及预后判断。     

CD_4~+CD_(25)~+调节性T细胞在儿科临床的实用价值

CD4+CD25+Treg细胞可分为天然性Treg细胞和获得性/诱导性Treg细胞。在病毒感染过程中,CD4+CD2+5Treg细胞维持机体对病毒的免疫耐受状态,促进病毒感染并导致其慢性化。CD4+CD2+5Treg细胞在幼年特发性关节炎的发病过程中发挥重要作用。哮喘患儿血CD4+T淋巴细胞表面的烟碱样乙酰胆碱受体(nAChRα7)表达增加,CD4+CD2+5FoxP3+Treg细胞明显减少。特发性血小板减少性紫癜患儿体内存在自身反应性T细胞的活动及细胞因子的紊乱,CD4+CD25highFoxP3+Treg细胞数量减少。体内外有效诱导、扩增和控制CD4+CD2+5Treg细胞的技术将会为相关儿科疾病的治疗提供崭新思路和有效方法。     

Involvement of CD4^＋CD25^＋ regulatory T cells in the pathogenesis of polycythaemia vera

Background Regulatory T cells （mreg） have been shown to play an important role in the regulation of hematopoietic activity. However, there is no information about the effect of Treg cells in the pathogenesis of polycythaemia vera （PV）. Methods In this study, we investigated the percentage and function of Treg cells in the peripheral blood of 21 PV patients and 25 healthy donors, mreg cells were identified and characterized as CD4^＋CD25^＋FOXP3^＋ by flow cytometry. The suppressive activity of CD4^＋CD25^＋ Treg cells was assessed by the proliferation and cytokine secretion of the co-cultured CD4^＋CD25^- fractions. Results The results showed that the percentage of Treg cells in the peripheral blood of PV patients significantly increased compared to healthy controls （（10.93±4.02）% vs （5.86±1.99）%, P 〈0.05）. Moreover, the mRNA and protein expression of FOXP3 was higher in CD4^＋CD25^＋ Treg cells. Coordinately, when co-cultured with the activated CD4^＋CD25^- cells, the CD4^＋CD25^＋ Treg cells showed enhanced suppressive function in PV. Yet, the underlying mechanism for the increased frequency and function of CD4^＋CD25^＋ Treg cells is still to be clarified. Conclusion Treg cells expansion might account for the abnormal T cell immunity in PV patients and thus contribute to the pathogenesis of PV.     

肾移植受者外周血中CD4~+ CD25~+ FoxP3~+调节性T细胞比例在评价其免疫状态中的作用

目的结合转移体内迟发超敏反应检测法初步探讨外周血中CD4+CD25+FoxP3+Treg的比例对亲体肾移植受者免疫状态评估的作用。方法收集西南医院肾科门诊随访的2005-2008年间手术的亲体肾移植供者和受者各30例,进行转移体内迟发超敏反应检测(trans-vivodelayed type hypersensitivity-assay,Transvivo-DTH)实验,根据实验结果将患者分为耐受组和排斥组;运用流式细胞技术检测2组中受者外周血单个核细胞(PBMCs)中CD4+CD25+FoxP3+Treg比例。结果耐受组和排斥组裸鼠掌肿胀(同时注入受者PBMCs和供者抗原的脚掌)厚度分别为(1.72±0.44)×10-2、(8.05±2.26)×10-2mm,前者明显高于后者(P<0.05),2组受者外周血中CD4+CD25+FoxP3+Treg的比例分别为(9.23±1.79)%和(1.03±1.04)%,耐受组明显高于排斥组(P<0.05)。耐受组和排斥组裸鼠脚掌皮下炎性水肿的厚度均与外周血中CD4+CD25+FoxP3+Treg的比例呈负相关(P<0.05,r分别为0.82和0.87)。结论受者外周血中CD4+CD25+FoxP3+Treg的比例能够反应受者T细胞对供者抗原发生免疫反应的程度。外周血中CD4+CD25+FoxP3+Treg的比例在发现移植受者是否已有耐受方面有一定的参考价值。     

α-黑素细胞刺激素对EAE豚鼠外周血CD4＋CD25＋FoxP3＋Treg细胞比例的影响

目的探讨α-MSH对EAE发病保护作用及免疫学机制。方法 40只雌性豚鼠随机分为正常对照组、EAE对照组和EAE高、低剂量治疗组。采用粗制髓鞘碱性蛋白（cMBP）诱发急性EAE,EAE高、低剂量治疗组自造模前7d始分别按1mg/（kg.d）及0.25mg/（kg.d）予腹腔注射注射α-MSH直至试验结束。观察豚鼠神经功能障碍评分变化,并用流式细胞方法测定CD4＋CD25＋FoxP3＋Treg细胞比例。结果 EAE高、低剂量治疗组神经功能障碍评分较EAE对照组显著降低（P〈0.01,P〈0.05）,高剂量治疗组降低更明显（P〈0.05）。EAE对照组豚鼠发病高峰期外周血CD4＋CD25＋FoxP3＋Treg细胞比例较正常对照组下降（P〈0.01）,高、低剂量治疗组CD4＋CD25＋FoxP3＋Treg细胞比例较EAE对照组升高（P〈0.01,P〈0.05）以高剂量治疗组升高最显著（P〈0.05）。EAE各组豚鼠发病高峰期外周血CD4＋CD25＋FoxP3＋Treg细胞比例与高峰期神经功能障碍评分呈负相关（r=-0.83,P〈0.05）。结论α-MSH对EAE豚鼠发病具有保护作用,其作用机制可能是通过增加外周血CD4＋CD25＋FoxP3＋Treg比例,增强对活化的自身反应性T细胞的抑制,发挥调节作用的。     

重症肌无力患者外周血CD4+ CD25+调节性T细胞与抗乙酰胆碱受体抗体和转化生长因子β1含量的相关性

目的 探讨重症肌无力(MG)患者外周血CD4+CD25+调节性T(Treg)细胞数量与血清抗乙酰胆碱受体抗体(AChR-Ab)和转化生长因子(TGF)-β1含量的相关性.方法 前瞻性地纳入40例新近发病或加重的MG住院患者和38名年龄、性别匹配的健康对照,应用流式细胞仪检测外周血CD4+ CD25+ Treg细胞数量,酶联免疫法检测血清TGF-β1含量,放免法检测血清AChR-Ab滴度,并对三者进行了相关性分析.结果 MG患者外周血CD4+CD25+Treg细胞百分率(3.0%±2.5%)显著低于健康对照(4.6%±3.7%,P=0.03).发病晚、病程长、抗AChR-Ab阳性、胸腺正常或退化以及未接受胸腺切除治疗等因素与MG患者CD4+CD25+Treg细胞减低有关.在31例非胸腺瘤MG(non-MGT)患者中,血清TGF-β1含量(112 ng/L±83 ng/L)显著低于健康对照(215 ng/L±134 ng/L,P=0.00),但在MG各临床亚型之间差异无统计学意义.虽然MG患者CD4+ CD25+Treg细胞百分率与血清AChR-Ab滴度不呈线性相关,但在非MGT患者中二者呈负相关(r=-0.37,P=0.02).非MGT患者血清AChR-Ab滴度还与Osserman临床分型和MGFA评分之间呈正相关(均r=0.34,P=0.03).非MGT患者血清TGF-β1含量与美国MG协会(MGFA)评分和CD4+CD25+Treg细胞百分率无相关性.结论 MG患者外周血CD4+CD25+Treg细胞百分率和血清TGF-β1含量均明显低于健康对照,可能参与了MG的发病.非MGT患者中Treg细胞百分率与AChR-Ab滴度呈负相关,检测其水平可能对评估MG病情及治疗提供理论依据,但是应用于临床还需要更多的相关研究.     

退白颗粒联合NB-UVB对白癜风患者外周血T细胞亚群的影响

目的 检测白癜风患者外周血CD4+、CD8+T细胞及CD4+CD25+调节性T细胞（Treg）的水平,同时对退白颗粒联合NB-UVB治疗后两者的水平进行检测,探讨两者与该病的关系。方法 采用流式细胞仪对120例白癜风患者及30例健康对照组外周血CD4+、CD8+T细胞及CD4+CD25+Treg细胞水平进行检测,同时120例患者分为3组,各40例。联合治疗组采用退白颗粒联合NB-UVB治疗、对照Ⅰ组采用单独NB-UVB治疗,对照Ⅱ组采用退白颗粒治疗,疗程为3月,对3组患者治疗前后CD4+/CD8+比值及CD4+CD25+Treg水平与健康对照组进行比较。结果 白癜风患者外周血CD4+T淋巴细胞明显降低,而CD8+T淋巴细胞则明显升高,与健康对照组比较均有统计学差异（P＜0.01）;进展期患者CD4+/CD8+比值明显低于稳定期（P＜0.01）,稳定期与健康对照组比较无统计学差异（P＞0.05）;白癜风患者CD4+CD25+Treg细胞百分率明显低于健康对照组（P＜0.01）,且进展期患者CD4+CD25+Treg细胞比稳定期下降更明显（P＜0.01）。采用退白颗粒联合NB-UVB治疗后CD4+/CD8+比值及CD4+CD25+Treg明显上调,与单独NB-UVB和单独退白颗粒治疗比较,差异有显著性意义（P＜0.01或P＜0.05）。结论 CD4+/CD8+比值的失衡与CD4+CD25+Treg数量的异常可能参与了白癜风的发病,退白颗粒联合NB-UVB可能通过调节两者的水平对该病发挥治疗作用。